Trial Profile
A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 22 Jun 2017 New trial record